InventisBio Soars 11.61% to Hit Intraday High of CNY 20.50

InventisBio, Co., a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a significant surge in its stock price, gaining 11.61% on March 27, 2026. The stock reached an intraday high of CNY 20.50, marking a notable performance against the backdrop of the China Shanghai Composite, which only rose by 0.63% on the same day. Over the past week, InventisBio has shown a robust increase of 13.07%, contrasting with a decline of 1.09% in the broader market. However, its performance over the past month reflects a slight downturn, with a decrease of 6.33%. Year-to-date, the stock has faced challenges, down 26.62%, while its one-year performance stands at a modest gain of 5.32%. Despite these fluctuations, key financial metrics indicate areas of concern, including a negative return on equity of -7.10% and a debt-to-equity ratio of -0.92. The company has reported losses, with a net profit of CNY -124.8 million in the latest half-year results. As InventisBio navigates its financial landscape, the recent stock activity highlights its current market position amidst ongoing challenges.